Year: 2006
Type: article
Abstract: Alzheimer’s disease (AD) is the most common form of dementia and accounts for major cognitive impairment in the elderly. It is a progressive neurodegenerative disorder with distinct pathology. At present, the pharmacotherapy of AD involves the use of acetylcholinesterase inhibitors and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine. The former imply neuroprotection hence slowing disease progression while the latter may block neuronal excitotoxicity.
Source: OAR@UM (University of Malta)
Author: Charles Scerri
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2585135146
